BioCentury
ARTICLE | Company News

Bavarian Nordic deal

October 10, 2011 7:00 AM UTC

Bavarian's BN ImmunoTherapeutics Inc. subsidiary received exclusive, worldwide rights to CVAC-301 (formerly Panvac) to treat certain cancers, including breast, lung and ovarian cancers, from the National Cancer Institute. Terms were not disclosed. CVAC-301 is in a Phase II trial for metastatic breast cancer, with data expected in 1H12. NCI regained rights to CVAC-301 after the previous licensee, Therion Biologics Corp., declared bankruptcy in 2006. The product is comprised of two separate vectors, each of which contains genes encoding carcinoembryonic antigen (CEA) and mucin 1 (MUC-1; CD227), plus three costimulatory molecules: CD58 (LFA-3), intercellular adhesion molecule-1 ( ICAM-1; CD54) and CD80 (B7-1). ...